Results 51 to 60 of about 24,117 (172)

MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients

HemaSphere
Administration of memantine, an antagonist of the N‐methyl‐ d‐aspartate receptor, prevents Ca2+ overload and dehydration of red blood cells (RBCs) in patients with sickle cell disease (SCD).
Ariel Koren, Carina Levin, Leonid Livshits, Fabio Valeri, Sari Peretz, Sivan Raz, Anna Yu Bogdanova, Max Gassmann   +7 more
doaj   +1 more source

Inhibitory Effect of NMDA Receptors in the Ventral Tegmental Area on Hormonal and Eating Behavior Responses to Stress in Rats

Behavioural Neurology, 2014
Background. Stress and its consequences are among the causes of accidents. Objective. The effects of intraventral tegmental area (I-VTA) memantine on the plasma corticosterone and eating parameters disturbance induced by acute stress were investigated ...
Zohreh Sadat Nasihatkon, Maryam Khosravi, Zahra Bourbour, Hedayat Sahraei, Mina Ranjbaran, Seyedeh Maryam Hassantash, Mohammad Sahraei, Kefayat Baghlani   +7 more
doaj   +1 more source

Long-Term NMDAR Antagonism Correlates Weight Loss With Less Eating

Frontiers in Psychiatry, 2019
Memantine hydrochloride is an uncompetitive N-methyl-D-aspartate (NMDA) antagonist for treatment of moderate-to-severe Alzheimer's disease. Several studies have shown that memantine can significantly correct the binge-like eating behavior in human and ...
Shi-Ning Deng, Yu-Hua Yan, Tai-Lin Zhu, Bing-Ke Ma, Hui-Ran Fan, Yan-Mei Liu, Wei-Guang Li, Fei Li   +7 more
doaj   +1 more source

An Electronic Health Record “Nudge” to Reduce Antipsychotic Medication Prescribing for Primary Care Patients With Dementia: A Pragmatic RCT

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background We hypothesized that an electronic health record (EHR) alert grounded in behavioral science could reduce new antipsychotic medication prescriptions for older adults with dementia. Methods We conducted a pragmatic clinical trial at a large academic health system, randomizing providers to receive the alert (intervention) or not ...
Catherine A. Sarkisian, Chad Wes Villaflores, Anne M. Walling, Sitaram S. Vangala, Eric M. Cheng, Suzanne Bliven Shu, Ajaya Pillai, Grace Y. Cheng, Noah Goldstein, John Mafi   +9 more
wiley   +1 more source

Pharmacodynamics of memantine: an update.

, 2008
Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimer s disease (AD) in Europe on 17(th) May 2002 and shortly thereafter was also ...
Rammes, G;Danysz, W;Parsons, CG
core   +1 more source

Chronic memantine decreases nicotine self-administration in rats.

, 2023
Neurobehavioral bases of tobacco addiction and nicotine reinforcement are complex, involving more than only nicotinic cholinergic or dopaminergic systems.
Levin, Edward D, Wells, Corinne, Hawkey, Andrew B, Rezvani, Amir H, Rose, Jed E, Yao, Leah, Nangia, Anica, Pippen, Erica, Howard, Sarah, Guo, Wendi   +9 more
core   +1 more source

Differential impact of N-Methyl-D-Aspartate Receptor antagonists on genes involved in synaptic plasticity and neural glucose metabolism: implication for psychosis. [PDF]

, 2011
Background: NMDA-R-hypofunction (NRH) is considered one of the putative molecular mechanism involved in psychosis. Several studies show that an imbalance of dopamine–glutamate transmission has a key role in psychosis pathophysiology.
Sarappa, Chiara
core   +1 more source

Memantine: Reality and Potentiality

, 2008
Memantine protects cultured neurons from excitotoxin-induced cell-death; it attenuated loss of cholinergic neurons in the CNS induced by injection of NMDA into the basal forebrain of rats.
Rita Moretti, Rodolfo M. Antonello, Cristina Vilotti, Rita Moretti M.D., Paola Torre, Davide Manganaro, Luca Zanet   +6 more
core   +1 more source

Interactions of memantine and rivastigmine with graphene oxide nanocarrier and beta-amyloid protein using molecular docking and in-silico methods

Heliyon
Alzheimer's disease is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles. Effective therapeutic strategies involve inhibiting the formation of beta-amyloid aggregates and destabilizing existing ones.
Fateme Davoudi, Nasrin Shadjou, Mahdieh Darroudi   +2 more
doaj   +1 more source

Integrating Pharmacogenomic Testing Within the 4Ms Framework for Management of Behavioral Symptoms in Advanced Vascular Dementia: A Case Study

Journal of the American Geriatrics Society, EarlyView.
Pharmacogenomic‐guided managment of behavioral symptoms within the 4Ms framework.
Gianna Franco, Collins Njoku, Mary L. Wagner, Fred A. Kobylarz   +3 more
wiley   +1 more source